X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bay-59-7939 (143) 143
rivaroxaban (119) 119
humans (117) 117
index medicus (101) 101
venous thromboembolism (84) 84
pharmacodynamics (81) 81
prevention (81) 81
pharmacokinetics (78) 78
factor-xa inhibitor (71) 71
factor xa inhibitors (59) 59
male (59) 59
anticoagulants (56) 56
peripheral vascular disease (54) 54
hematology (53) 53
administration, oral (52) 52
female (50) 50
safety (50) 50
pharmacology & pharmacy (47) 47
middle aged (45) 45
thromboprophylaxis (38) 38
total hip-replacement (38) 38
dose-response relationship, drug (37) 37
aged (36) 36
morpholines - administration & dosage (36) 36
thiophenes - administration & dosage (36) 36
bay 59-7939 (35) 35
enoxaparin (35) 35
adult (34) 34
morpholines - adverse effects (34) 34
morpholines - therapeutic use (34) 34
thiophenes - adverse effects (34) 34
thiophenes - therapeutic use (34) 34
anticoagulants - administration & dosage (33) 33
anticoagulants - adverse effects (33) 33
anticoagulants - therapeutic use (33) 33
deep-vein thrombosis (33) 33
thromboembolism (32) 32
morpholines - pharmacology (31) 31
thiophenes - pharmacology (31) 31
in-vitro (30) 30
venous thromboembolism - prevention & control (30) 30
morpholines - pharmacokinetics (29) 29
thiophenes - pharmacokinetics (29) 29
factor xa inhibitor (26) 26
animals (22) 22
arthroplasty (22) 22
aged, 80 and over (21) 21
anticoagulants - pharmacology (21) 21
atrial fibrillation (21) 21
thrombosis (21) 21
treatment outcome (21) 21
blood coagulation - drug effects (20) 20
anticoagulants - pharmacokinetics (19) 19
prothrombin time (19) 19
replacement (19) 19
thrombin (19) 19
antithrombotic agent (17) 17
double-blind method (16) 16
analysis (15) 15
anticoagulation (15) 15
arthroplasty, replacement, knee - adverse effects (15) 15
double-blind (15) 15
surgery (15) 15
warfarin (15) 15
anticoagulants - blood (14) 14
cardiac & cardiovascular systems (14) 14
dosage and administration (14) 14
drug interactions (14) 14
morpholines - blood (14) 14
thiophenes - blood (14) 14
venous thrombosis - prevention & control (14) 14
adolescent (13) 13
arthroplasty, replacement, hip - adverse effects (13) 13
dabigatran (13) 13
drug therapy (13) 13
healthy-subjects (13) 13
population pharmacokinetics (13) 13
stroke (13) 13
total knee arthroplasty (13) 13
young adult (13) 13
atrial fibrillation - drug therapy (12) 12
enoxaparin - therapeutic use (12) 12
hemorrhage - chemically induced (12) 12
molecular-weight heparin (12) 12
time factors (12) 12
venous thromboembolism - etiology (12) 12
anticoagulant (11) 11
antithrombotic therapy (11) 11
blood (11) 11
enoxaparin - adverse effects (11) 11
factor xa inhibitors - administration & dosage (11) 11
fibrinolytic agents - administration & dosage (11) 11
health aspects (11) 11
medicine, general & internal (11) 11
partial thromboplastin time (11) 11
postoperative complications - prevention & control (11) 11
risk factors (11) 11
factor xa (10) 10
factor xa inhibitors - adverse effects (10) 10
medical examination (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


THROMBOSIS AND HAEMOSTASIS, ISSN 0340-6245, 09/2008, Volume 100, Issue 3, pp. 453 - 461
Rivaroxaban (Xarelto(R)) is an oral, direct factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders.... 
BAY-59-7939 | HEALTHY-SUBJECTS | SAFETY | pharmacodynamics | total hip replacement | rivaroxaban | population pharmacokinetics | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | DRUGS | PERIPHERAL VASCULAR DISEASE | factor Xa | HEMATOLOGY | Population pharmacokinetics | Rivaroxaban | Factor Xa | Pharmacodynamics | Total hip replacement
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2010, Volume 103, Issue 4, pp. 815 - 825
Journal Article
JOURNAL OF CLINICAL PHARMACOLOGY, ISSN 0091-2700, 05/2006, Volume 46, Issue 5, pp. 549 - 558
To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939... 
ranitidine | BAY-59-7939 | BAY 59-7939 | antacid | SAFETY | PREVENTION | PHARMACODYNAMICS | food | REPLACEMENT | VENOUS THROMBOEMBOLISM | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | direct factor Xa inhibitor
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2776 - 2786
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 02/2012, Volume 107, Issue 2, pp. 379 - 387
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 01/2011, Volume 9, Issue 1, pp. 133 - 139
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
Aims The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism
Journal Article